ICG clearance depends on liver blood flow and uptake and is rather insensitive to changes in biliary excretion (5, 6). In contrast, BSP clearance is critically dependent on biliary excretion (7). We therefore postulated that BSP and ICG pharmacokinetic parameters might provide an accurate assessment of the overall histological severity of PBC by evaluating the degree of bile duct paucity and cholestasis on the one hand, and the degree of hepatocyte necrosis, fibrosis, or cirrhosis on the other hand.
Primary biliary cirrhosis (PBC) is a chronic cholestatic disease most often diagnosed in middle-aged women. 3 Morphologically, PBC is characterized by a chronic nonsuppurative cholangitis affecting small and medium-sized bile ducts, leading to the destruction and loss of intrahepatic bile ducts. As in all long-term obstructive cholestasis, lobular lesions and cirrhosis may occur. The terminal phase is characterized by hyperbilirubinemia (>100 mol/L), a greatly decreased number of patent intrahepatic bile ducts, and extensive fibrosis or cirrhosis. Orthotopic liver transplantation is currently the treatment of choice for end-stage patients, with a two-year survival rate as great as 80% (1).
Among the drugs evaluated in controlled trials for the medical therapy of PBC, cyclosporine and ursodeoxycholic acid are very promising (2) (3) (4) .
To assess the effects of medical treatment on the progression of the characteristic lesions of PBC, i.e., destruction of bile ducts and hepatocytes and the development of fibrosis and cirrhosis, there is a crucial need for quantitative liver-function tests. The concentration of serum bilirubin is a specific marker of entry into the ' ICG clearance depends on liver blood flow and uptake and is rather insensitive to changes in biliary excretion (5, 6). In contrast, BSP clearance is critically dependent on biliary excretion (7). We therefore postulated that BSP and ICG pharmacokinetic parameters might provide an accurate assessment of the overall histological severity of PBC by evaluating the degree of bile duct paucity and cholestasis on the one hand, and the degree of hepatocyte necrosis, fibrosis, or cirrhosis on the other hand.
To test this hypothesis, we devised a mixed BSP-ICG test and applied it to 50 patients with PBC to assess the usefulness of BSP-ICG pharmacokinetics in the diagnosis of PBC and in the quantification of histological progression of the disease.
PatIents and Methods

Patients
Fifty PBC patients were included in the study. The diagnosis was based on accepted criteria (1). Histological liver specimens were all examined by the same pathologist and classified as follows: stage I, chronic nonsuppurative cholangitis; stage II, portal and periportal infl,mamgtion and fibrosis with ductular proliferation; stage ifi, lobular fibrosis with bridging; stage IV, cirrhosis.
We also performed the BSP-ICG test with a control group of 15 apparently healthy subjects. constructed for each patient. BSP concentrations in serum were determined by measuring the absorbance of alkalinized serum at 580 nm relative to an acidified sample blank. The data derived from the plasma and serum disappearance curves were fitted to a biexponential function (C = Ae + Be) by using the graphic method of residuals (11). Briefly, in the terminal part of the curve (after 30 mm), the first distribution phase (C = Ae) was considered to be negligible. Thus, the slope of the terminal regression line is equal to /3and the In addition, "fractional clearance," k1, was computed from the slope,,f the least-squares regression line for the experimental data and determined in the initial phase of the curve (from 4 to 20 mm after the injection). The BSP terminal elimination rate (k2) was considered equal to the value of /3. Finally, the BSP retention percentage at 45 mm was deduced from the extrapolated BSP concentration at time zero: % retention (BSP) at 45 miii = 100 x C(BSP) at 45 min/(A + B).
BSP-ICGTest
Statistical Analysis
Data (mean ± SD) were compared by using KruskallWallis nonparametric analysis of variance and the Mann-Whitney U-test. Differences were considered significant at P <0.01.
Results
The data are summarized in Table 1 . Mean ICG fractional clearance (k1) and hepatic clearance (Cl) were within the normal range in the PBC patients, except for those with stage IV disease.
BSP hepatic clearance was significantly reduced, .89, P <0.001; Figure 1 ). There was a significant correlation (r = 0.64; P <0.01) between the BSP retention percentage at 45 mm and the area under the second part of the biexponential curve (AUC/3 = B/$).
Typical patterns of BSP-ICG disappearance from the serum and plasma, respectively, of a PBC patient (stage II) and a healthy subject are presented in Figure 2 .
DIscussIon
We have shown the feasibility of measuring ICG and BSP pharmacokunetics simultaneously. Regarding possible BSP-ICG interaction, studies in rats (12,13) and dogs (12) have shown a competitive inhibition of hepatocyte BSP uptake by ICG (13). Meijer et al. (14) also observed enhanced ICG clearance in the presence of dibromosulfophthaleun, probably attributable to an increase in the plasma protein-unbound ICG fraction. However, they used a molar BSP/ICG ratio in the range of 1 to 10, whereas our conditions (BSPIICG = 19.7) make it unlikely that the decreased BSP clearance was related to ICG-induced inhibition of uptake processes.
Furthermore, the values in the mixed BSP-ICG test observed with healthy subjects did not differ from those obtained with separate BSP and ICG tests (data not shown).
The two dyes showed distinct plasma disappearance patterns, whatever the severity of PBC. ICG elimination was monophasic, with a clearance value not significantly different from that of the controls, except in the stage IV (cirrhotic) disease. These findings are in agreement with previous studies that showed that cholestasis has little or no influence on ICG clearance in humans (5). This is supported by the physiology of ICG hepatic extraction: the decreased clearance of ICG in patients with stage IV disease is consistent with functional flow-limited uptake of the dye (5).
BSP showed a biphasic elimination profile, whatever the stage, unlike that found in healthy subjects. The greater the histological severity, the lower the biliary elimination, as reflected by either the k2 constant or the 45-min retention percentage.
In PBC, cholestasis is caused by the destruction of interlobular and septal bile ducts, with a progressive loss of bile ducts as the disease progresses towards cirrhosis (15) . This is entirely consistent with the progressive decrease in the k2 constant and the 45-min retention percentage we found. Thus, The BSP elimination constant, k1, was markedly reduced in stage N disease, suggesting that cholestasis is associated with decreased uptake in these patients. In this case, BSP parallels the elimination profile of lOG, a pattern that is also observed in cirrhotic patients of alcoholic or posthepatitic origin (data not shown).
Data concerning the metabolism of BSP and ICG might be useful for the interpretation of these results. Both anions are initially retnoved from the plasma by a 
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